Opus Point Partners Management as of June 30, 2015
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 55 positions in its portfolio as reported in the June 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Receptos | 4.2 | $5.3M | 28k | 190.05 | |
| Seattle Genetics | 4.0 | $5.0M | 104k | 48.40 | |
| BioMarin Pharmaceutical (BMRN) | 3.9 | $4.9M | 36k | 136.77 | |
| Proshares Ultra Nasdaq Biotechnology Etf Etf (BIB) | 3.8 | $4.8M | 54k | 90.39 | |
| Illumina (ILMN) | 3.7 | $4.7M | 22k | 218.36 | |
| Clovis Oncology | 3.7 | $4.6M | 52k | 87.88 | |
| Nektar Therapeutics (NKTR) | 3.7 | $4.6M | 368k | 12.51 | |
| Alkermes (ALKS) | 3.6 | $4.6M | 71k | 64.35 | |
| Biogen Idec (BIIB) | 3.6 | $4.5M | 11k | 403.95 | |
| Regeneron Pharmaceuticals (REGN) | 3.5 | $4.5M | 8.8k | 510.10 | |
| Celgene Corporation | 3.5 | $4.4M | 38k | 115.73 | |
| Incyte Corporation (INCY) | 3.5 | $4.4M | 42k | 104.22 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.5 | $4.4M | 35k | 123.48 | |
| Alnylam Pharmaceuticals (ALNY) | 3.3 | $4.2M | 35k | 119.87 | |
| Medivation | 3.1 | $3.9M | 34k | 114.20 | |
| Cepheid | 3.1 | $3.9M | 64k | 61.15 | |
| Alexion Pharmaceuticals | 3.1 | $3.9M | 22k | 180.78 | |
| ISIS Pharmaceuticals | 3.0 | $3.8M | 66k | 57.55 | |
| Mettler-Toledo International (MTD) | 3.0 | $3.8M | 11k | 341.45 | |
| Qiagen | 2.8 | $3.5M | 140k | 24.79 | |
| Bio-techne Corporation (TECH) | 2.7 | $3.3M | 34k | 98.47 | |
| Pacira Pharmaceuticals (PCRX) | 2.6 | $3.3M | 47k | 70.72 | |
| AstraZeneca (AZN) | 2.5 | $3.2M | 50k | 63.72 | |
| Array BioPharma | 1.8 | $2.3M | 322k | 7.21 | |
| Hologic (HOLX) | 1.4 | $1.8M | 48k | 38.06 | |
| Tesaro | 1.4 | $1.8M | 30k | 58.80 | |
| Epizyme | 1.4 | $1.7M | 72k | 24.00 | |
| SPDR S&P Biotech Put Option (XBI) | 1.1 | $1.4M | 1.0k | 1350.00 | |
| Vericel (VCEL) | 1.0 | $1.3M | 362k | 3.57 | |
| Assembly Biosciences | 1.0 | $1.3M | 65k | 19.26 | |
| Esperion Therapeutics (ESPR) | 1.0 | $1.2M | 15k | 81.73 | |
| Flamel Technologies | 0.9 | $1.1M | 52k | 21.18 | |
| United Therapeutics Corporation (UTHR) | 0.7 | $939k | 5.4k | 173.92 | |
| Nanostring Technologies (NSTGQ) | 0.7 | $925k | 60k | 15.42 | |
| Ultragenyx Pharmaceutical (RARE) | 0.7 | $922k | 9.0k | 102.44 | |
| Merrimack Pharmaceuticals In | 0.7 | $890k | 72k | 12.36 | |
| Chimerix (CMRX) | 0.7 | $885k | 19k | 46.21 | |
| D Stemline Therapeutics | 0.7 | $883k | 75k | 11.77 | |
| Infinity Pharmaceuticals (INFIQ) | 0.7 | $876k | 80k | 10.95 | |
| Amgen (AMGN) | 0.7 | $852k | 5.6k | 153.51 | |
| XenoPort | 0.6 | $797k | 130k | 6.13 | |
| Curis | 0.6 | $712k | 215k | 3.31 | |
| Ocera Therapeutics | 0.6 | $709k | 187k | 3.80 | |
| Biodel | 0.5 | $670k | 650k | 1.03 | |
| Relypsa | 0.5 | $596k | 18k | 33.11 | |
| Achillion Pharmaceuticals | 0.5 | $591k | 67k | 8.86 | |
| Arrowhead Research | 0.5 | $587k | 82k | 7.15 | |
| Zogenix | 0.4 | $504k | 300k | 1.68 | |
| Gilead Sciences (GILD) | 0.4 | $496k | 4.2k | 117.15 | |
| Wts/repros Therapeutics Inc. Series B 2.4500 Exp02/07/2016 WTS Call Option | 0.4 | $456k | 98k | 4.65 | |
| Acelrx Pharmaceuticals | 0.3 | $424k | 100k | 4.24 | |
| Kalobios Pharmaceuticals | 0.3 | $358k | 747k | 0.48 | |
| National Holdings | 0.3 | $321k | 90k | 3.59 | |
| Juno Therapeutics | 0.2 | $270k | 5.1k | 53.40 | |
| Neptune Technologies Bioreso | 0.0 | $1.0k | 15.00 | 66.67 |
